secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001213900-23-039291
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX Q1 net loss $6.4M; cash $30.3M; positive Part 1 BX004 data; PIPE closed
-----------------------------------------------------------------------------

- Net loss $6.4M vs $8.2M YoY; R&D expense $4.6M; cash $30.3M as of March 31, 2023.
- Positive Phase 1b/2a Part 1 BX004 results: >90% reduction in P. aeruginosa CFU; no safety events; Part 2 data expected Q3 2023.
- Completed $7.5M PIPE with OrbiMed and CF Foundation; second closing in May 2023.
- Jason M. Marks and Michael E. Dambach appointed to Board of Directors.
- Cash runway sufficient into Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/ea178578-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer